Company Performance Metrics
- Dr. Sebastian Eriksson Giwa: Founder, CEO and CTO
At Sylvatica, we’re reimagining human health. We strive to transform organ transplantation, trauma care, oncofertility and regenerative medicine through technology that stops or controls biological time.
The ability to replace organs and tissues on demand could save or improve millions of lives each year globally and create public health benefits
on par with curing cancer. Unmet needs for organ and tissue preservation place enormous logistical limitations on transplantation, regenerative medicine, drug discovery, and a variety of rapidly advancing areas spanning biomedicine.
Sylvatica is developing a novel, non-toxic approach to bank human organs, enable global organ matching and save millions of lives. We use strategies employed in nature and augment with complementary bioengineering principles.
Sylvatica was recently featured as a NIH success story: https://sbir.nih.gov/stories/sylvatica
See also www.nature.com/nbt/journal/v35/n6/full/nbt.3889.html and sylvaticabio.com
